Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 26
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Castle Biosciences Inc
CSTL
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$33.30
0.22
0.67%
Dern. MÀJ: Oct 26, 4:22 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Résultats:
Résultats Q3 2026 dans dans 10 jours à partir de maintenant le jeu. nov. 5th, après la fermeture du marché
Castle Biosciences Financials
Castle Biosciences (CSTL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Castle Biosciences Raises FY2026 Sales Guidance from $345.000M-$355.000M to $365.000M-$375.000M vs $352.291M Est
Castle Biosciences (NASDAQ:CSTL) raises FY2026 sales outlook from $345.000 million-$355.000 million to $365.000 million-$375.000 million vs $352.291 million estimate.
Benzinga Newsdesk
PRO
Castle Biosciences Q2 Adj. EPS $(0.07) Beats $(0.41) Estimate, Sales $103.546M Beat $86.240M Estimate
Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.41) by 82.93 percent. This is a 146.67 percent decrease over earnings of $0.15 per share
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
Castle Biosciences Raises FY2026 Sales Guidance from $340.000M-$350.000M to $345.000M-$355.000M vs $345.734M Est
Castle Biosciences (NASDAQ:CSTL) raises FY2026 sales outlook from $340.000 million-$350.000 million to $345.000 million-$355.000 million vs $345.734 million estimate.
Benzinga Newsdesk
PRO
Castle Biosciences Q1 Adj. EPS $(0.49), Inline, Sales $83.700M Beat $79.415M Estimate
Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.49) per share which met the analyst consensus estimate. This is a 145 percent decrease over losses of $(0.20) per share from the same period last year.
Benzinga Newsdesk
Castle Biosciences Q4 Earnings Assessment
Benzinga Insights
